A Phase 3 Clinical Study for People With Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis

STUDY GOALS:

  • To find out if AL amyloidosis patients treated with MLN9708 plus dexamethasone respond better than patients treated with other chemotherapies that physicians use
  • To determine if MLN9708 plus dexamethasone can change the chance that amyloidosis will cause the heart and/or kidneys to begin to work poorly, leading to hospitalization or death

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Have relapsed or refractory AL amyloidosis
  • Have received 1 or 2 prior therapies for AL amyloidosis
  • Are 18 years of age or older
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT
AL AMYLOIDOSIS

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
To learn more about
this study, call:
1-888-559-7901
Monday–Friday 9am–7pm ET

After hours?

Provide your contact information and we'll call you back.